Lexicon Pharmaceuticals, Inc. (LXRX) — Financial statements
Income statement, balance sheet, and cash flow for Lexicon Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 50↑60.2% | 31↑2481.5% | 1↑766.2% | 0.14↓53.4% | 0.30 | |
| Cost of Revenue | 0.27↓55.5% | 0.62↓99.0% | 59↑12.3% | 53↓4.6% | 55 | |
| Gross Profit | 50↑62.6% | 30↑152.7% | -58↓10.3% | -52↑4.3% | -55 | |
| Operating Expenses | ||||||
| R&D Expenses | 61↓27.7% | 84↑43.5% | 59↑11.5% | 53↓4.1% | 55 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 37↓71.7% | 132 | 0.00 | 0.00 | 0.00 | |
| Other Expenses | 0.00↓100.0% | 11↓79.7% | 55↑1342.8% | -4↑80.5% | -23 | |
| Operating Expenses | 98↓56.7% | 228↑99.7% | 114↑135.6% | 48↑49.6% | 32 | |
| Total Costs & Expenses | 99↓56.7% | 228↑31.9% | 173↑71.4% | 101↑15.5% | 87 | |
| Operating Results | ||||||
| Operating Income | -49↑75.2% | -197↓14.8% | -172↓70.5% | -101↓15.7% | -87 | |
| Depreciation & Amortization | 0.62↑16.3% | 0.53↓3.6% | 0.55↑29.7% | 0.43↑46.2% | 0.29 | |
| EBITDA | -48↑73.8% | -184↓8.6% | -170↓69.7% | -100↓15.2% | -87 | |
| EBIT | -49↑73.5% | -185↓8.5% | -170↓69.5% | -100↓15.4% | -87 | |
| Interest & Other Income | ||||||
| Net Interest Income | -1↑56.5% | -3↑38.8% | -5↓353.5% | -1↓77.2% | -0.67 | |
| Interest Income | 7↓43.8% | 12↑59.0% | 8↑384.5% | 2↑1091.0% | 0.13 | |
| Interest Expense | 8↓46.5% | 16↑18.9% | 13↑371.3% | 3↑246.6% | 0.80 | |
| Non-Operating Income | 0.00↑100.0% | -12↓753.7% | -1↓380.0% | -0.30 | 0.00 | |
| Other Income / Expenses | -1↑56.5% | -3↑38.8% | -5↓353.5% | -1↓77.2% | -0.67 | |
| Income Before Tax | -50↑74.9% | -200↓13.1% | -177↓73.7% | -102↓16.2% | -88 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -50↑74.9% | -200↓13.1% | -177↓73.7% | -102↓16.2% | -88 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -50↑74.9% | -200↓13.1% | -177↓73.7% | -102↓16.2% | -88 | |
| Bottom-Line Net Income | -50↑74.9% | -200↓13.1% | -177↓73.7% | -102↓16.2% | -88 | |
| EPS (Basic) | -0.14↑77.8% | -0.63↑21.3% | -0.80↓29.0% | -0.62↓1.6% | -0.61 | |
| EPS (Diluted) | -0.14↑77.8% | -0.63↑21.3% | -0.80↓29.0% | -0.62↓1.6% | -0.61 | |
| Weighted Average Shares | 363↑13.4% | 320↑44.7% | 221↑33.4% | 166↑13.8% | 146 | |
| Weighted Average Diluted Shares | 363↑13.4% | 320↑44.7% | 221↑33.4% | 166↑13.8% | 146 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.